Literature DB >> 25575035

Preleukemia: the normal side of cancer.

Liran I Shlush1, Mark D Minden.   

Abstract

PURPOSE OF REVIEW: In the present review, we will define the preleukemic state. We aim at increasing awareness and research in the field of preleukemia that will nurture targeted therapy for the earlier steps of leukemia evolution. RECENT
FINDINGS: Emerging evidence supports the role of hematopoietic stem/progenitor cells carrying recurrent leukemia-related mutations as the cell of origin of both myeloid and lymphoid malignancies. The preleukemic stem cells can maintain at least to some extent their functionality; however, they have increased fitness endowed by the preleukemic mutations that lead to clonal expansion.
SUMMARY: The latent preleukemic period before overt leukemia presents can take years, and the majority of carriers will never develop leukemia in their lifetime. The preleukemic state is not rare, with greater than 1% of individuals having acquired one or more of the recognized preleukemic lesions. The high frequency of such abnormalities in the population may be the cost of growing old; however, another view could be that in order to survive to old age, the hematopoietic system must adapt to create robust hematopoietic stem/progenitor cells with an increased fitness and clonal expansion. Hence, leukemia does not necessarily start as a disease, but rather as a need, with the normally functioning preleukemic hematopoietic stem cells trying to maintain health for years but in time succumbing to their own acquired virtues.

Entities:  

Mesh:

Year:  2015        PMID: 25575035     DOI: 10.1097/MOH.0000000000000111

Source DB:  PubMed          Journal:  Curr Opin Hematol        ISSN: 1065-6251            Impact factor:   3.284


  11 in total

1.  Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes.

Authors:  David P Steensma; Rafael Bejar; Siddhartha Jaiswal; R Coleman Lindsley; Mikkael A Sekeres; Robert P Hasserjian; Benjamin L Ebert
Journal:  Blood       Date:  2015-04-30       Impact factor: 22.113

2.  Inhibition of Inflammatory Signaling in Tet2 Mutant Preleukemic Cells Mitigates Stress-Induced Abnormalities and Clonal Hematopoiesis.

Authors:  Zhigang Cai; Jonathan J Kotzin; Baskar Ramdas; Sisi Chen; Sai Nelanuthala; Lakshmi Reddy Palam; Ruchi Pandey; Raghuveer Singh Mali; Yan Liu; Mark R Kelley; George Sandusky; Morvarid Mohseni; Adam Williams; Jorge Henao-Mejia; Reuben Kapur
Journal:  Cell Stem Cell       Date:  2018-12-06       Impact factor: 24.633

Review 3.  Aging, clonal hematopoiesis and preleukemia: not just bad luck?

Authors:  Liran I Shlush; Sasan Zandi; Shalev Itzkovitz; Andre C Schuh
Journal:  Int J Hematol       Date:  2015-10-06       Impact factor: 2.490

Review 4.  Understanding the molecular basis of acute myeloid leukemias: where are we now?

Authors:  Alicja M Gruszka; Debora Valli; Myriam Alcalay
Journal:  Int J Hematol Oncol       Date:  2017-11-17

5.  Zfp521 promotes B-cell viability and cyclin D1 gene expression in a B cell culture system.

Authors:  Salma Al Dallal; Kathryn Wolton; Kathryn E Hentges
Journal:  Leuk Res       Date:  2016-04-09       Impact factor: 3.156

6.  Low numbers of pre-leukemic fusion genes are frequently present in umbilical cord blood without affecting DNA damage response.

Authors:  Pavol Kosik; Milan Skorvaga; Matus Durdik; Lukas Jakl; Ekaterina Nikitina; Eva Markova; Katarina Kozics; Eva Horvathova; Igor Belyaev
Journal:  Oncotarget       Date:  2017-05-30

7.  Socio-demographic Characteristics of Patients with Diagnosis of Leukemia in Bosnia and Herzegovina During Six-year Period.

Authors:  Edo Hasanbegovic; Nedim Begic; Snijezana Hasanbegovic; Zijo Begic
Journal:  Mater Sociomed       Date:  2016-12

8.  Regnase-1-mediated post-transcriptional regulation is essential for hematopoietic stem and progenitor cell homeostasis.

Authors:  Hiroyasu Kidoya; Fumitaka Muramatsu; Teppei Shimamura; Weizhen Jia; Takashi Satoh; Yumiko Hayashi; Hisamichi Naito; Yuya Kunisaki; Fumio Arai; Masahide Seki; Yutaka Suzuki; Tsuyoshi Osawa; Shizuo Akira; Nobuyuki Takakura
Journal:  Nat Commun       Date:  2019-03-06       Impact factor: 14.919

Review 9.  The Impact of the Cellular Origin in Acute Myeloid Leukemia: Learning From Mouse Models.

Authors:  James Neil Fisher; Natarajaswamy Kalleda; Vaia Stavropoulou; Juerg Schwaller
Journal:  Hemasphere       Date:  2019-01-30

Review 10.  Ponatinib and other CML Tyrosine Kinase Inhibitors in Thrombosis.

Authors:  Peng Zeng; Alvin Schmaier
Journal:  Int J Mol Sci       Date:  2020-09-08       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.